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Note
Decline of Dosage Regimen Patents in Light of
Emerging Next-Generation DNA Sequencing
Technology and Possible Strategic Responses
Na An, Ph.D.*
The successful launch of a pharmaceutical product requires
an investment of billions of dollars and carries significant risks,
mostly due to the complexity of pharmaceutical sciences,
intricacy of the regulatory scheme, intensive competition, high
marketing cost, and the continuing change of intellectual
property law.1 To obtain returns sufficient to recoup their
investments and fund further research, pharmaceutical
companies place great focus on devising and pivoting strategies
to strengthen and extend their rights of exclusivity.2 One chief
practice is to build a strong patent portfolio, keeping
competitors at bay and ensuring an advantageous position
when litigation arises.3 A carefully managed patent strategy
provides protection not only to the chemical composition of the
drug, but also to new developments and improvements of the
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1. Jason Millman, Does it Really Cost $2.6 Billion to Develop a New
Drug?, WASH. POST (Nov. 18, 2014), https://www.washingtonpost.com
/news/wonk/wp/2014/11/18/does-it-really-cost-2-6-billion-to-develop-a-new-
drug/.
2. Carolyne Hathaway, John Manthei & Cassie Scherer, Exclusivity
Strategies in the United States and European Union, UPDATE, May/June 2009,
at 34, https://www.lw.com/upload/pubcontent/_pdf/pub2655_1.pdf.
3. Brenda Herschbach Jarrell & William B. Asher, Lifecycle
Management: Patent Prosecution Strategies in Pharmaceutical and
Biotechnology Cases, CHOATE HALL & STEWART LLP (2007),
https://www.choate.com/uploads/113/doc/lifecycle-management-patent-
prosecution-strategies.pdf.
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basic compound.4 These follow-on patents may bring
significant values to their owners in both defensive and
offensive postures.5 In addition to strengthening, or even
extending the terms of, these patents, careful management of
the secondary patents can minimize the risk of being blocked
by competitors second generation patents and being
prevented from practicing certain embodiments within their
basic composition patent.6
Patents directed to dosage regimens of a drug are one
important example of these follow-on improvements.7 Dosage
regimens relate to the modality of drug administration,
including formulation, route of administration, drug dose,
dosing interval, and treatment duration.8 These dosage
decisions are made to maximize a desired set of responses and
minimize an undesired set of responses.9 Part of the clinical
trial for new chemical entities involves verifying dosage
regimens to evaluate their therapeutic value as per Food and
Drug Administration (FDA) request.10 However, determining
the appropriate dosage regimen for a drug is particularly
difficult, because patients responses to drugs are
multifactorial, multigenetic, and coupled with low treatment
adhesion rates.11 Consequently, pharmaceutical companies
4. Patents: Pharmaceutical Product Patenting Strategies, LEMAN
CONSULTING S.A. 12, http://www.lemanconsulting.ch/doc
/GB_PATENT_Product_patenting_strategies.pdf (last visited Feb. 29, 2016).
5. Id.
6. Id. at 1.
7. Id. at 2.
8. See Roger L. Williams, Dosage Regimen Design: Pharmacodynamic
Considerations, 32 J. CLINICAL PHARMACOLOGY 597, 59799 (1992)
(explaining how drug effect can be measured in terms of several different
positive and negative actions over time); Dosage Regimen, U. LAUSANNE,
http://sepia.unil.ch/pharmacology/index.php?id=76 (last visited Feb. 29, 2016).
9. Williams, supra note 8, at 598.
10. U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: DOSAGE AND
ADMINISTRATION SECTION OF LABELING FOR HUMAN PRESCRIPTION DRUG AND
BIOLOGICAL PRODUCTSCONTENT AND FORMAT 3 (Mar. 2010),
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformat
ion/Guidances/ucm075066.pdf [hereinafter GUIDANCE FOR INDUSTRY: DOSAGE
AND ADMINISTRATION].
11. See, e.g., Stephen E. Kimmel, Warfarin Therapy: In Need of
Improvement After All These Years, 9 EXPERT OP. PHARMACOTHERAPY 677,
680 (2008) ([A] large proportion of interpatient variability in warfarin
response remains unexplained. This variability is consistent with multigenetic
effects on drug response.). Another example is Daptomycin (Cubicin), an
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invest significantly in research and development to comply
with FDA requirements and simplify dosage regimens for
increased patient adherence.12 Failure or delay to file for patent
protection on dosage regimens may allow competitors to claim
their own invention and affect the brand companys freedom-
to-operate on . . . [the] product under development.13
Therefore, competent patent attorneys should use dosage
regimen patents to ensure optimum protection of
pharmaceutical products.
Drug discovery has taken a drastically different trajectory
after the introduction of personalized medicine, shifting from
exclusively focusing on developing new blockbuster chemical
entities to embracing tailored therapeutics.14 Scientists and
medical professionals have long recognized that patients
respond to drugs differently, largely influenced by age, gender,
genetic makeup, environmental factors, life style, body mass
index, and so on.15 However, the lack of scientific ability to
antibiotic used to treat infections, including those resistant to vancomycin, a
commonly used antibiotic. Its application has not been easy due to various
adverse effects upon different patient population. See Barry Fox & Sarah E.
Bland, UMHC Guidelines for the Use of Deptomycin (Cubicin®), U. WIS. HOSP.
& CLINICS (Feb. 2011), http://www.uwhealth.org/files/uwhealth
/docs/antimicrobial/Daptomycin.pdf. For a review article explaining common
challenges, see Stella M. Davies, Pharmacogenetics, Pharmacogenomics and
Personalized Medicine: Are We There Yet?, 1 HEMATOLOGY 111, 111 (2006).
12. Improving Prescription Medicine Adherence is Key to Better Health
Care, PHRMA 6 (Jan. 2011), http://phrma.org/sites/default/files/pdf
/PhRMA_Improving%20Medication%20Adherence_Issue%20Brief.pdf. See
generally Matthew Herper, How Much Does Pharmaceutical Innovation Cost?
A Look At 100 Companies, FORBES (Aug. 11, 2013, 11:10 AM),
http://www.forbes.com/sites/matthewherper/2013/08/11/the-cost-of-inventing-
a-new-drug-98-companies-ranked/#91a392616284 (presenting the empirical
results of the authors research into the costs of inventing, developing, and
ultimately marketing new pharmaceutical drugs).
13. Patents: Pharmaceutical Product Patenting Strategies supra note 4, at
3.
14. Rebecca Henderson & Cate Reavis, Eli Lilly: Recreating Drug
Discovery for the 21st Century, MASS. INST. TECH. SLOAN SCH. MGMT. 1 (Mar.
13, 2008), https://mitsloan.mit.edu/LearningEdge/CaseDocs/07-043-
Recreating-Drug-Discovery.pdf.
15. Personalized Medicine, NATL INST. HEALTH (Oct. 7, 2015),
https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-
health/personalized-medicine; see also U.S. FOOD & DRUG ADMIN., PAVING THE
WAY FOR PERSONALIZED MEDICINE: FDAS ROLE IN A NEW ERA OF MEDICAL
PRODUCT DEVELOPMENT 19 (Oct. 2013), http://www.fda.gov
/downloads/ScienceResearch
/SpecialTopics/PersonalizedMedicine/UCM372421.pdf [hereinafter PAVING
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predict an individual patients treatment success for most
diseases and conditions has forced clinicians to follow a less
than optimal approach to prescribing drugs: one size fits all.16
Fortunately, rapid technological developments on genomic
DNA sequencing have enabled advances in our understanding
of human genetics and its influences on disease and
treatment.17 Initiated by the National Human Genome
Research Institute, the development of next-generation DNA
sequencing technologies brought the cost of the whole human
genome sequencing down to $1000 in 2015.18 This
breakthrough will help close the tremendous gap in human
genetic variation data and treatment responsea giant step
towards realizing personalized medicine.19
Correlation of drug dosage regimens to specific patients
with a particular genetic makeup will allow for optimal
treatment results and the development of new uses for known
drugs.20 Therefore, genetic testing must be performed and
interpreted by medical professionals before dosage regimens
can be determined for individual patients. The testing and
interpretation processes will most likely be performed outside
of the R&D department of pharmaceutical companies.21 These
developments in personalized medicine will not only raise
regulatory challenges, but also restructure the pharmaceutical
THE WAY FOR PERSONALIZED MEDICINE]. See generally W. Ken Redekop &
Deirdre Mladsi, The Faces of Personalized Medicine: A Framework for
Understanding its Meaning and Scope, 16 VALUE IN HEALTH S4, S4 (2013).
16. See PAVING THE WAY FOR PERSONALIZED MEDICINE, supra note 15, at
6; LJ Lesko, Personalized Medicine: Elusive Dream or Imminent Reality?, 81
Clinical Pharmacology & Therapeutics 807, 808 (2007) ([t]he one size fits all
dosing paradigm is not precise enough and new approaches are needed to
define the right dose.).
17. PERSONALIZED MED. COALITION, THE CASE FOR PERSONALIZED
MEDICINE 4 (4th ed. 2014), http://www.personalizedmedicinecoalition.org
/Userfiles/PMC-Corporate/file/pmc_the_case_for_personalized_medicine.pdf.
18. Press Release, George Church, Co-Founder, Veritas Genetics, Veritas
Genetics Breaks $1,000 Whole Genome Barrier (Sept. 29, 2015),
https://www.veritasgenetics.com/documents/VG-PGP-Announcement-
Final.pdf.
19. THE CASE FOR PERSONALIZEDMEDICINE, supra note 17, at 1920.
20. Id.
21. For a discussion on future landscape of clinical testing in both hospital
and independent lab settings, see The Future for Hospital and Independent
Labs in the U.S. Clinical Testing Market, KALORAMA INFO.,
http://www.kaloramainformation.com/article/2014-01/Future-Hospital-and-
Independent-Labs-US-Clinical-Testing-Market (last visited Mar. 1, 2016).
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industry, especially their strategies to patent portfolio
management. Section I of this note introduces the background
information regarding personalized medicine, dosage regimens,
and the emergency of next-generation DNA sequencing
technology and its impact on the medical practice. Section II
discusses current patent strategies surrounding dosage
regimens and the ramifications of individualized prescriptions.
Section II also explores the regulatory difficulties FDA
confronts with the new sequencing technology and potential
policy changes. Section III examines available IP strategies
that pharmaceutical companies could adopt to accommodate
these changes in a new healthcare era.
I. BACKGROUND
A. DRUG DOSAGE REGIMENS IN PERSONALIZEDMEDICINE
A dosage regimen is the modality of drug administration,
including formulation, route of administration, drug dose,
dosing interval, and treatment duration.22 Determining the
right dosage regimen, paramount to safe and effective drug
development, is required by FDA for a new drug application23
and requires a significant capital investment.24 Yet, dosage
regimens are difficult to define for certain drugs.25 The most-
cited case study involves the drug warfarin, which has been
used for the treatment and long-term prevention of
thromboembolism.26 It has been more than a half century
since the FDA approved warfarin as an oral anticoagulant,
but, despite decades of clinical use, rates of adverse events
22. Dosage Regimen, supra note 8; see alsoWilliams, supra note 8, at 598.
23. See generally GUIDANCE FOR INDUSTRY: DOSAGE AND
ADMINISTRATION, supra note 10, at 28 (providing the FDAs detailed
guidelines for setting and communicating the dosage regimen of a drug).
24. SeeMillman, supra note 1 (discussing the recent study Cost to Develop
and Win Marketing Approval for a New Drug is $2.6 Billion, TUFTS CTR. FOR
STUDY DRUG DEV. (Nov. 18, 2014), http://csdd.tufts.edu/news/complete_story
/pr_tufts_csdd_2014_cost_study).
25. See generally Dominik Selzer et al., Finite and Infinite Dosing:
Difficulties in Measurements, Evaluations and Predictions, 65 ADV. DRUG
DELIVERY REVS. 278, 278 (2013) (analyzing the problems commonly associated
with dosages of drugs that are applied to the skin); see also Brian L. Erstad,
Which Weight for Weight-Based Dosage Regimens in Obese Patients?, 59 AM. J.
HEALTH-SYS. PHARMACY 2105, 2105 (2002) (describing the role of a patients
weight in determining proper dosage.
26. Kimmel, supra note 11, at 678.
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from this well-known drug [are] still among the highest of all
commonly prescribed outpatient drugs in the world.27
Unfortunately, as one of very few available oral drugs for
thromboembolism prevention, warfarin is [also] the tenth most
commonly prescribed medication in the US.28 Bleeding . . .
occurs in up to 41% of patients treated with warfarin, leading
to medical complications and deprivation of therapy.29 The
principal issue associated with administer[ing] warfarin is the
biological heterogeneity and comorbidity of the[] patients and
the drugs narrow therapeutic index, which causes significant
interindividual variability in patients responses.30 Although
the [recommended] average maintenance dose is 4  6 mg per
day, [practically,] there is a very wide range of doses (such as
4.5  77 mg per week[]) required to achieve the same [level of
anticoagulation control] among different patients.31 As a
result, patients prescribed with warfarin are strongly advised
to wear medical alerts.32 To promote drug safety and protect
public health, a better understanding of the multifactorial and
multigenetic drug responses from individual patients is of high
importance in modern pharmaceutical science.
Traditional drug development and clinical approaches to
design dosage regimens vary significantly among different
therapeutic areas and a drugs benefit/risk analysis.33 However,
the basic concept is to provide a simple and easy [dosing
paradigm] for physicians and patients to understand and use[,
. . . which is frequently] referred to as the one size fits all
concept of dosing.34 During the course of treatment, the doctor
makes a decision based on the recommended dosing paradigm;
27. Lesko, supra note 16, at 808.
28. Kimmel, supra note 11, at 678.
29. Id.
30. Lesko, supra note 16, at 808; see also Elizabeth A. Sconce et al., The
Impact of CYP2C9 and VKORC1 Genetic Polymorphism and Patient
Characteristics Upon Warfarin Dose Requirements: Proposal for a New Dosing
Regimen, 106 BLOOD 2329, 2329 (2005) (Patients are at greatest risk of
overanticoagulation during the initiation period . . . . These early problems are
due principally to the widespread interindividual variation in response to the
warfarin loading dose, explained in part by patient age and genotype.).
31. Kimmel, supra note 11, at 679 (footnote omitted).
32. Michael A. Chen, Taking Warfarin (Coumadin), MEDLINEPLUS (Jan.
9, 2015), https://www.nlm.nih.gov/medlineplus/ency/patientinstructions
/000292.htm.
33. Lesko, supra note 16, at 808.
34. Id.
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if the medication does not have the desired effect after a few
weeks, the patient will be put on a different regimen or a new
drug.35 This trial-and error approach can lead to patient
dissatisfaction, adverse drug responses and drug interactions[,
delay of treatment,] and poor [patient] adherence to treatment
regimens.36 Warfarin, discussed above, is a paramount
example of this concern.37 The need for a therapy with the
right drug at the right dose in the right patient is highlighted
by the fact that adverse drug reactions may rank as the fifth
leading cause of death in the United States.38
[A]pproximately 3.1 billion prescriptions are issued in the
United States [per year], of which approximately 2.1 million
result in an adverse reaction. One million prescriptions form
this latter group may result in hospitalization, and of these
more than 100,000 patients may die.39
Recognizing individual differences in drug responses is an
essential step towards optimizing therapy. A substantial
portion of variability in drug response is genetically
determined, [requiring consideration of] age, [nutrition, health
status, ethnicity, gender,] environmental exposure, and
concurrent therapy.40 Several terms have been used
interchangeably with personalized medicine, one of which,
precision medicine, is perhaps most synonymous and has
been defined by the National Academy of Science (NAS) as the
use of genomic, epigenetic, exposure and other data to define
individual patterns of disease, potentially leading to better
individual treatment.41 Such precision medicine is achieved by
a stratification process that divides patients with a particular
disease into subgroups, based on a characteristic of some sort,
35. See PAVING THE WAY FOR PERSONALIZED MEDICINE, supra note 15, at
6.
36. Id.
37. Supra text accompanying notes 2732.
38. Laviero Mancinelli, Maureen Cronin & Wolfgang Sadée,
Pharmacogenomics: The Promise of Personalized Medicine, 2 AAPS PHARMSCI
1, 2 (2000).
39. Id. at 10.
40. Id. at 1.
41. See PAVING THE WAY FOR PERSONALIZED MEDICINE, supra note 15, at
6. For a thorough discussion of the scope and definition of personalized
medicine, see W. Ken Redekop & Deirdre Mladsi, The Faces of Personalized
Medicine: A Framework for Understanding Its Meaning and Scope, 16 VALUE
IN HEALTH S4 (2013).
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who respond more frequently to a particular drug or,
alternatively, are at a decreased risk of side effects.42 Then,
dosage regiments are designed specifically for a subgroup
instead of for all patients.43
Personalized medicine has been proposed to revolutionize
modern healthcare and medical practice in several ways.44
First, it introduces the ability to use molecular markers that
signal disease risk and shifts the focus from treatment to
prevention and early intervention.45 A good example is found
in women with certain BRCA1 or BRCA2 gene variations
who, compared to the general female population, have a much
higher chance of developing breast (85% v. 13%) and ovarian
cancers (60% v. 1.7%).46 Through genetic testing, patients can
benefit from suggested preventive measures including lifestyle
changes and disease-monitoring options.47 Secondly,
personalized medicine will guide dosage regimen design and
reduce trial-and-error prescribing, thus decreasing adverse
effects.48 Studies have shown that 38 percent of depression
patients, 50 percent of arthritis patients, 40 percent of asthma
patients, and 43 percent of diabetic patients will not respond to
initial treatment positively.49 The majority of patients, for
example, have at least one DNA-based variation in the
enzymes that metabolize half of the most commonly prescribed
medicines.50 Thus, [t]he use of genetic . . . screening allows
42. See PAVING THE WAY FOR PERSONALIZED MEDICINE, supra note 15, at
6, 8 (Stratification can be thought of as a core element of personalized
medicine.).
43. Id.
44. See generally Alan Haruo Bryce & Robert McWilliams, Current Status
and Future Directions of Personalized Medicine, 5 GENOME MED. 62 (2013)
(providing an overview of major topics evolving in personalized medicine,
including genomic techniques and their clinical applications as well as
relevant regulatory implications); see also Fatiha H. Shabaruddin, Nigel D.
Fleeman & Katherine Payne, Economic Evaluations of Personalized Medicine:
Existing Challenges and Current Developments, 8 PHARMACOGENOMICS &
PERSONALIZED MED. 115, 115 (2015) (It is often argued that personalizing
treatment will inevitably improve clinical outcomes for patients and help
achieve more effective use of health care resources.).
45. THE CASE FOR PERSONALIZEDMEDICINE, supra note 17, at 8.
46. Id.
47. Id. at 89.
48. Id. at 9.
49. Id.
50. Id.
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the physician to select an optimal therapy the first time,
increasing patient adherence and avoiding high costs.51
At the core of personalized medicine are more accurate and
individualized dosage regimen designs, which take the center
stage of technical advances52 and are guided by
pharmacogenomics, the study of variations of DNA and RNA
characteristics [(genomics)] as related to drug response.53 The
first big scientific driver in personalized medicine was the
discovery of cytochrome P450 metabolic enzymes and their role
in chemically modifying the drug molecules so they can be
removed from the bloodstream; thus, variations in these
enzymes can have significant impacts on the effective dosage
regimens of the drug.54 The next real drive occurred with the
sequencing of the whole human genome in 2003, which cost
$2.7 billion and took thirteen years to complete.55 The cost and
time for sequencing human genomes have declined over the
years, but we still face challenges to fully implement these
51. Id. For more examples of genetic-based drug response, see LM
Mangravite et al., Clinical Implications of Pharmacogenomics of Statin
Treatment, 6 PHARMACOGENOMICS J. 360, 360, 369 (2006) (evaluating the role
of genetics in statin pharmacogenomics); Mark J. Rieder et al., Effect of
VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose, 352
NEW ENG. J. MED. 2285, 2285 (2005) (Variants in the gene encoding vitamin
K epoxide reductase complex 1 (VKORC1) may affect the response to
warfarin.); Steven G. Terra et al., β1-Adrenergic Receptor Polymorphisms and
Left Ventricular Remodeling Changes in Response to β-Blocker Therapy, 15
PHARMACOGENETICS & GENOMICS 227, 233 (2005) (If confirmed in future
studies, particularly those evaluating clinical outcomes, targeted heart failure
therapy based on an individual genotype might be done at some point in the
future. Given the number of standard therapies now available for heart
failure, such an approach might allow for more rational prescribing, and use of
alternative therapies in those patients deriving minimal benefit from a "-
blocker.).
52. PAVING THE WAY FOR PERSONALIZED MEDICINE, supra note 15, at 6.
See generally Marilyn N. Martinez et al., Dosing Regimen Matters: The
Importance of Early Intervention and Rapid Attainment of the
Pharmacokinetic/Pharmacodynamic Target, 56 ANTIMICROBIAL AGENTS &
CHEMOTHERAPY 2795, 2795, 2804 (2012).
53. PAVING THEWAY FOR PERSONALIZED MEDICINE, supra note 15, at 8.
54. Ulrich M. Zanger & Matthias Schwab, Cytochrome P450 Enzymes in
Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and
Impact of Genetic Variation, 138 PHARMACOLOGY & THERAPEUTICS 103, 104
(2013).
55. The Human Genome Project Completion: Frequently Asked Questions,
NATL HUM. GENOME RES. INST., http://www.genome.gov/11006943 (last
updated Oct. 30, 2010).
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technologies in a clinical setting and effectively correlate the
data with dosage regimen design.56
B. NEXT-GENERATION DNA SEQUENCING TECHNOLOGY
Recent efforts in clinical implementation of
pharmacogenomics have proved to be challenging, some of the
chief reasons including: delay in genomic testing, lack of . . .
large-scale genomic data linked to automated clinical decision
support, . . . uncertainty of clinical benefits . . . for genome-
guided therapy, and . . . financial concerns with regard to
genomic medicine.57 These difficulties can, to a certain extent,
be attributed to deficiencies in current human genome
sequencing technologies.58 For example, the long delay and
high cost to perform a sequencing test deter these efforts,
resulting in too little data collected to make meaningful
correlations between genetic variations and optimal clinical
decisions.59 Therefore, a groundbreaking improvement in
human genome sequencing technology is a vital part of
successful implementation of personalized medicine.
DNA sequencing technology has a rich and diverse history,
and it embodies interplay among chemistry, engineering,
software, and molecular biology.60 The first two widely-known
56. See Nan Myers, The Challenges of Personalized Medicine, PENN MED.
Spring 2009, at 1415, http://www.uphs.upenn.edu/news/publications
/PENNMedicine/files/PENNMedicine_2009_02_spring14_personalized_medici
ne.pdf (People have an incredible optimism for personalized medicine [b]ut
. . . the reality today is very different. It is a very complicated process, both
creating a test and getting the test to the point where it can actually be used
in a clinical setting.) (quoting Dr. Pamela Sankar, assistant professor of
bioethics at Penns Center for Bioethics); see also Casey Lynnette Overby &
Peter Tarczy-Hornoch, Personalized Medicine: Challenges and Opportunities
for Translational Bioinformatics, 10 PERSONALIZED MED. 453, 45859 (2013)
(summarizing the challenges and conclusions about the future of personalized
medicine).
57. See Suzette J. Bielinski et al., Preemptive Genotyping for Personalized
Medicine: Design of the Right Drug, Right Dose, Right TimeUsing Genomic
Data to Individualize Treatment Protocol, 89 MAYO CLINIC PROC. 25, 26
(2014).
58. Id.; see Shabaruddin, Fleeman & Payne, supra note 44, at 116.
59. Myers, supra note 56, at 15; Shabaruddin, Fleeman & Payne, supra
note 44, at 123.
60. See Lisa D. White, History of DNA Sequencing Technologies, in Next
Generation Sequencing: Translation to Clinical Diagnostics 10 (Lee-Jun C.
Wong ed., 2013); Clyde A. Hutchison III, DNA Sequencing: Bench to Bedside
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methods for DNA sequencing appeared in 1977: the Maxam-
Gilbert and Sanger sequencing methods, both relying on
separation of DNA fragments with gel electrophoresis.61 Both
methods suffer from a demand for large quantities of materials,
low accuracy, and high labor intensity.62 Due to its superior
simplicity and reliability, Sanger sequencing became the
dominant method in the 1990s, especially after the
incorporation of fluorescence labeling and capillary
instrument.63 Coupled with advances of computer science,
these second-generation DNA sequencing instruments were
taken up broadly by the research market by 2008 after the
cost of whole-genome sequencing costs fell from between $100
$300 million in 2001 to about $10 million in 2007.64
As a response to an initiative from the National Human
Genome Research Institute that aimed at developing
sequencing technology of the entire genome for less than $1000,
the industry devoted significant efforts to developing
sequencing technologies at a much faster rate than ever
experienced.65 The resulting next-generation sequencing
technologies feature characteristics such as low cost, fast
analysis, high accuracy, and low sample volume.66
For example, in May 2011, Illumina announced that it had
lowered the price for sequencing the whole human genome to
$5000 per individual67 and in January 2014 introduced a new
and Beyond, 35 NUCLEIC ACIDS RES. 6227, 622731 (2007); Miodrag Guvić,
The History of DNA Sequencing, 32 J. MED. BIOCHEMISTRY 301, 302 (2013).
61. Guvić, supra note 60, at 302.
62. Id. at 30204.
63. Id. at 304; Elaine R. Mardis, Next-Generation Sequencing Platforms, 6
ANN. REV. ANALYTICAL CHEMISTRY 287, 290 (2013).
64. THE CASE FOR PERSONALIZEDMEDICINE, supra note 17, at 18.
65. Press Release, Natl Hum. Genome Res. Inst., NHGRI Seeks Next
Generation of Sequencing Technologies: New Grants Support Development of
Faster, Cheaper DNA Sequencing (Oct. 14, 2004),
https://www.genome.gov/12513210; Jason M. Rizzo & Michael J. Buck, Key
Principles and Clinical Application of Next-Generation DNA Sequencing, 5
CANCER PREVENTION RES. 887, 887 (2012); see also Chandran Anandhakumar
et al., Advancing Small-Molecule-Based Chemical Biology with Next-
Generation Sequencing Technologies, 16 CHEMBIOCHEM 20, 36 (2015); Mardis,
supra note 63, at 288, 30001.
66. Mardis, supra note 63, at 288, 300.
67. Bio-IT World Staff, Illumina Announces $5,000 Genome Pricing,
BIOIT WORLD (May 9, 2011), http://www.bio-itworld.com/news/05/09/2011
/Illumina-announces-five-thousand-dollar-genome.html. IGN [Illumina
Genome Network] is a global service partnership that links researchers
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instrument that can do the same job for just $1000.68 The
Illumina platform combines DNA biology and fluorescence
detection to achieve high throughput and accuracy.69 In spring
2014, Oxford Nanopore announced their MinION Access
Program to call research communities and industries to test
their $1000 whole genome sequencer.70 Nanopore technology
uses electrical fields to drive negatively charged DNA through
a nanometer channel, and the resulting electrical signatures
reveal the sequence of the DNA.71 With bioinformatics and long
MinION reads, scientists were able to achieve 99% accuracy
and resolve a cancer-testis gene family.72 In September 2015,
Veritas Genetics, as a part of the Personal Genome Project,
announced a $1000 full-genome sequencing service including
data interpretation.73 The Personal Genome Project is
dedicated to creating open public genome and health data for
the greater good.74 Thermo Fisher Scientific also entered the
interested in conducting large-scale whole human genome projects with
leading institutions that can perform such projects using Illumina
sequencers. Id.
68. Matthew Herper, The $1,000 Genome ArrivesFor Real, This Time,
FORBES (Jan. 14, 2014, 9:14 PM), http://www.forbes.com/sites/matthewherper
/2014/01/14/the-1000-genome-arrives-for-real-this-time/#388d378b61c9.
69. Anandhakumar et al., supra note 65, at 22; Press Release, Illumina,
Inc., Illumina Expands Worlds Most Comprehensive Next-Generation
Sequencing Portfolio (Jan. 12, 2015), http://www.illumina.com/company/news-
center/press-releases/press-release-details.html?newsid=2006979; see also
Roadmap Epigenomics Consortium et al., Integrative Analysis of 111 Reference
Human Epigenomes, 518 NATURE 317, 317 (2015).
70. Julia Karow, Oxford Nanopore to Select First Users for Early Access to
MinIon; Program Heavily Oversubscribed, GENOMEWEB (Jan. 28, 2014),
https://www.genomeweb.com/sequencing/oxford-nanopore-select-first-users-
early-access-minion-program-heavily-oversubsc.
71. Ron Ammar et al., Long Read Nanopore Sequencing for Detection of
HLA and CYP2D6 Variants and Haplotypes, 4 F1000RES. 17, 17 (2015); Miten
Jain et al., Improved Data Analysis for the MinION Nanopore Sequencer, 12
NATUREMETHODS 351, 351 (2015).
72. Jain et al., supra note 71, at 351.
73. Alexandra Ossola, Your Full Genome Can Be Sequenced and Analyzed
for Just $1,000, POPULAR SCI. (Sept. 30, 2015), http://www.popsci.com/cost-
full-genome-sequencing-drops-to-1000.
74. Sharing Personal Genomes, PERS. GENOME PROJECT: HARV.,
http://www.personalgenomes.org (last visited Jan. 30, 2016).
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competitive industry by providing three types of whole genome
sequencers that cost around $1000.75
Meanwhile, other biotechnology companies are also getting
close to fast and inexpensive whole genome sequencing in this
heated race. Pacific Biosciences announced their Sequel
Sequencing System in September 2015 with an important
feature of detecting epigenetic markers in the genome in
addition to the natural sequence.76 Understanding the
epigenetic disorder provides another dimension into correlating
genetic variations to disease states, although the current
$350,000 cost of the system is much higher than sister
technologies.77 It is worth noting, however, that additional
costs and time are necessary for all analysis and annotation in
a clinical setting.
The next-generation DNA sequencing market is growing
rapidly and is expect[ed] to grow from its current size of 2.2
billon to 5.6 billion this year.78 Current market leader
Illumina enjoyed revenue growth of approximately 30% in
2014.79 Roche shook hands with Foundation Medicine in an
agreement worth nearly $1.2 billion.80 Pharmaceutical
companies have also recognized the potential benefits of next-
generation sequencing; [d]uring just part of 2015, Genentech
announced two agreements, and Pfizer announced one.81 The
large investments and intensive research efforts pouring into
the field prompt the following question: will the fast advance of
75. Whole Genome Sequencing, THERMOFISHER SCI.,
https://www.thermofisher.com/us/en/home/life-science/sequencing/dna-
sequencing/whole-genome-sequencing.html (last visited Jan 30, 2016).
76. PacBio Announces Sequel Sequencing System, BIOIT WORLD (Sept. 30,
2015), http://www.bio-itworld.com/2015/9/30/pacbio-announces-sequel-
sequencing-system.aspx.
77. Id.; see also Mark J. P. Chaisson et al., Resolving the Complexity of the
Human Genome Using Single-Molecule Sequencing, 517 NATURE 608, 608
(2015).
78. Next Generation Sequencing (NGS) Markets 2015, PR NEWSWIRE
(Mar. 5, 2015), http://www.prnewswire.com/news-releases/next-generation-
sequencing-ngs-markets-2015-300046436.html.
79. Id.; see also Press Release, Markets & Markets, Next Generation
Sequencing (NGS) Market Worth 10,371.1 Million USD by 2021, (Mar. 9,
2016), http://www.marketsandmarkets.com/PressReleases/ngs-
technologies.asp.
80. See Next Generation Sequencing (NGS) Markets 2015, supra note 78.
81. Id.
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next-generation DNA sequencing bring personalized medicine
to patients soon?
C. DOSAGE REGIMEN DESIGN IN THE ERA OF NEXT-GENERATION
DNA SEQUENCING
Thanks to the significant decrease in sequencing costs and
time afforded by NGS [next-generation sequencing]
technologies, it is becoming more cost-effective to resequence
entire human genomes from clinical samples and this will soon
be routine in the clinical practice of medicine.82 Currently,
targeted genetic tests are predominantly used as diagnostic
and prognostic tools in clinical oncology due to their low cost
and relatively simple interpretability.83 But, importantly,
whole genome sequencing requires no prior selection of
particular genes to be profiled and provides a global view of the
genome, which allow for the identification of novel alternations
and somatic mutations even in non-coding and unannotated
regions of the genome.84 High-coverage genomic data also
allows for the detection of chromosomal rearrangements . . . .
[and because t]he identity and distribution of genomic
alterations vary widely between cancer types, . . . mutational
signatures[] can be indicative of the underlying risk of cancer
development.85 For example, the authors in a 2011 case study,
in the course of treating a very difficult disease, identified an
abnormal gene rearrangement using next-generation
82. Rizzo & Buck, supra note 65, at 895; Eric D. Green, Mark S. Guyer &
Natl Hum. Genome Res. Inst., Charting a Course for Genomic Medicine from
Base Pairs to Bedside, 470 NATURE 204, 205 (2011); Stephen F. Kingsmore &
Carol J. Saunders, Deep Sequencing of Patient Genomes for Disease Diagnosis:
When Will it Become Routine?, 3 SCI. TRANSLATIONAL MED. 23, 1 (2011); see
RICHARD TUTTON, GENOMICS AND THE REIMAGINING OF PERSONALIZED
MEDICINE 153 (Ashgate ed., 2014); Joseph V. Thakuria, Principles and
Clinical Applications of Next-Generation DNA Sequencing, UPTODATE (July
27, 2015), http://www.uptodate.com/contents/principles-and-clinical-
applications-of-next-generation-dna-sequencing; see also Leslie G. Biesecker &
Robert C. Green, Diagnostic Clinical Genome and Exome Sequencing, 370
NEW ENG. J. MED. 2418, 2423 (2014); Christian Gilissen et al., Genome
Sequencing Identifies Major Causes of Severe Intellectual Disability, 511
NATURE 344, 344 (2014).
83. Rizzo & Buck, supra note 65, at 895.
84. Id.
85. Veronique G. LeBlanc & Marco A. Marra, Next-Generation Sequencing
Approaches in Cancer: Where Have They Brought Us and Where Will They
Take Us?, 7 CANCERS 1925, 1930 (2015).
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technology to sequence the whole genome early on and
successfully altered the treatment plan in a clinically relevant
time frame.86 Importantly, the genetic rearrangement was not
detectable using standard targeted sequencing.87
In addition to genome analysis, next-generation
sequencing can also be used to monitor gene expression, which
is particularly important for detecting cancer, a disease
characterized by global genomic dysregulation.88 Pacific
Bioscience, along with other companies, has developed a
system that can detect epigenetic modifications, the identity
and pattern of which regulate a variety of cellular functions
and progress of cancer.89 For example, an ovarian cancer study
used next-generation sequencing technology to monitor the
epigenetic difference between healthy and diseased individuals
and found a modification trend in patients at an area close to a
particular gene.90 Next-generation sequencing technology has
provided scientists and medical professionals unprecedented
access to the whole human genome at a cost of approximately
$1000.
As proponents of personalized medicine envision a future
where every person will have his or her whole genome
sequenced and linked to his or her medical record, allowing
physicians to develop a more holistic, personalized health care
strategy, there still remain obstacles to overcome. First, our
ability to collect data outpaces the medical communitys ability
to understand and act on it.91 Second, more available
sequencing data allows better understanding of disease and
cancers caused by genetic variations, but it does not directly
answer the question of how patients with a particular genetic
makeup will respond to a drug.92 More data and research are
86. John S. Welch et al., Use of Whole-Genome Sequencing to Diagnose a
Cryptic Fusion Oncogene, 305 JAMA 1577, 157879 (2011).
87. Id. at 1579.
88. LeBlanc & Marra, supra note 85, at 1931.
89. See PacBio Announces Sequel Sequencing System, supra note 76; see
generally Samantha Bhat et al., Biological Implications and Therapeutic
Significance of DNA Methylation Regulated Genes in Cervical Cancer, 121
BIOCHIMIE 298, 300 (2016); Javier Soto et al., The Impact of Next-Generation
Sequencing on DNA Methylation-Based Translational Cancer Research, 169
TRANSLATIONAL RES. 1, 8 (2016).
90. Soto et al., supra note 89, at 13.
91. THE CASE FOR PERSONALIZEDMEDICINE, supra note 17, at 20.
92. Myers, supra note 56, at 15.
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necessary to fully appreciate these correlations, but open and
public sharing of an individuals genomic data raises significant
privacy issues.93 Over time, health information technology will
advance, while researchers identify genetic variations that
correlate to disease and treatment response. And through
coalitions like the Personal Genome Project and legislative
efforts, personalized medicine will become a reality.
II. ANALYSIS
A. IMPACT OF PERSONALIZEDMEDICINE ON DOSAGE REGIMEN
PATENTS
The cost of developing a new drug depends on the type of
drug, the success rate, and whether the drug is a new
molecular entity (NME) or an incremental modification of an
existing drug.94 The research cost of developing an innovative
new drug . . . [is] more than $800 million, while most
incrementally modified drugs cost less.95 Adding marketing,
regulatory approval processes, and other expenses, recent
studies have shown that a successful launch of a new drug
costs, on average, $2.6 billion.96 Obtaining approval from the
DA to market the drug takes years to complete; more often
than not, pharmaceutical companies find themselves quickly
running out of patent terms on their newly-launched product.97
Therefore, strategies to preserve and extend market exclusivity
become paramount for pharmaceutical companies to acquire
sufficient returns to recoup investment and fund further
research.98
Building a strong patent portfolio is one essential part of
that strategy, which includes both basic protection of the
chemical entity (if it is a NME drug) and follow-on patents
93. M. Leeann Habte, Claire M. Marblestone & Jennifer M. Forde,
Privacy Issues in the Sharing of Genetic Information, FOLEY & LARDNER LLP,
Sept. 2014, at 1, https://www.foley.com/files/Publication/7465587b-5df9-4f85-
9969-68ce1b4c39af/Presentation/PublicationAttachment/88ba6035-c031-4ff4-
b4e2-6ad15030b17d/PrivacyIssuesintheSharingofGeneticInformation.pdf.
94. CONG. BUDGET OFF., RESEARCH AND DEVELOPMENT IN THE
PHARMACEUTICAL INDUSTRY 1, 2 (2006), https://www.cbo.gov/sites/default/files
/109th-congress-2005-2006/reports/10-02-drugr-d.pdf.
95. Id. at 2.
96. Millman, supra note 1.
97. Hathaway, Manthei & Scherer supra note 2, at 34.
98. Herschbach Jarrell & Asher, supra note 3.
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regarding improvements and new developments.99 For
incrementally modified drugs, only follow-on patents are
available under most circumstances.100 Among these secondary
filings, dosage regimens of the drug are commonly used, not
only because the FDA requires research data on the proper
administration of the drug, but also due to its large strategic
value.101 Dosage regimens are difficult to determine, as
demonstrated in the warfarin example discussed above,102 thus,
a large amount of money has to be spent to understand the
drugs toxicity and efficacy in various dosage regimens.
Branded drug companies naturally desire patent protection on
these discoveries.
More importantly, skilled patent attorneys use dosage
regimen patents in various strategies. First, more patents on a
product, basic and secondary, increases the possibility of
findings of validity, enforceability, and infringement in future
litigation which strengthens the portfolio and diminishes
uncertainty.103 Secondly, competitors could file for these
patents and raise freedom-to-operate issues for the branded
drug owner.104 Lastly, a lengthy FDA approval process cuts
deeply into the term of a patent family; companies often have
very few years of exclusivity left at the beginning of product
launch.105 With a remarkable number of blockbuster drugs
losing their patent protection in the next few years, companies
are desperate for any possible extension or continuation of their
exclusivity.106 Once a chemical composition is patented, it
becomes a prior art reference to any additional patent
application based around the compound or pharmaceutical
composition.107 Therefore, the new patent protections
generally encompasses narrow improvements or new uses for
99. Patents: Pharmaceutical Product Patenting Strategies, supra note 4, at
1.
100. See id.
101. Id. at 1, 45.
102. Kimmel, supra note 11, at 3.
103. See Patents: Pharmaceutical Product Patenting Strategies, supra note
4, at 45.
104. Id. at 5.
105. Hathaway, Manthei & Scherer supra note 2, at 34.
106. Michelle L. Cunningham & W. Murray Spruill, Strategies for
Extending the Life of Patents, 18 BIOPHARM, no. 3, Mar. 1, 2005,
http://www.biopharminternational.com/strategies-extending-life-patents.
107. Id.
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the pharmaceutical [compound] not disclosed or suggested in
the original patent.108
For example, new applications can be filed for new routes
of administration or dosing form to prevent adverse effect and
increase efficacy.109 The migraine drug Imitrex gained its
owner GlaxoSmithKline (GSK) annual sales of $1 billion
dollars; after the original patent directed to the compound
expired in 2006, GSK sought patent protection and FDA
approval on a new Imitrex for intranasal delivery.110
Alternatively, several pharmaceutical companies have
successfully obtained patent protection for new methods of
use.111 The two most famous examples are finasteride and
atomoxetine.112 Merck first patented and obtained FDA
approval on finasteride as a treatment for benign prostate
enlargement under the brand name Proscar. Additional patent
protection and FDA approval were sought when a new use for
finasteridetreating male pattern baldnesswas identified
. . . . [and] marketed under the brand name Propecia.113
Similarly, Eli Lilly initially investigated [atomoxetine] as a
treatment for depression and later discovered its efficacy in
treating attention deficit hyperactivity disorder.114 Lilly sought
additional patent protection and FDA approval for the new use,
bringing in more than two million prescriptions within first
nine months on the market.115 These strategies and
corresponding examples all relate to alternations of dosage
regimens to generate new products and additional patent
protection.
With the fast approach of personalized medicine, the use of
two medical products is usually involved: a diagnostic device
and a therapeutic product.116 Genetic testing will first be
conducted and interpreted before the doctor translates that









116. See PAVING THE WAY FOR PERSONALIZED MEDICINE, supra note 15, at
8.
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dosage regimen.117 Patients respond to drugs differently and as
a result, these dosage regimens cannot be determined until
genetic testing is performed.118 And instead of at the research
and development department of a pharmaceutical company,
these tests will be done in a hospital or a healthcare facility
long after the product has been on the market.119 Additionally,
the advent of mobile and wireless capability . . . allow for more
effective patient monitoring and treatment outside the
traditional medical care settings, potentially moving into a
patients home and work.120 What does this mean for the
dosage regimen patents that are so valuable to pharmaceutical
companies?
B. CURRENT JURISPRUDENCE ON DRUG DOSAGE REGIMEN
PATENTS
Unlike European countries, Japan, and China, dosage
regimen patents are treated as medical methods and
considered patentable subject matter in the US.121 However,
117. Id. at 6.
118. Id.
119. Id. at 9.
120. Id.
121. Jerry I-H Hsiao & Wei-Lin Wang, Dosage Patenting in Personalized
Medicine, B.C. INTELL. PROP. & TECH. F. 710 (2012), http://bciptf.org/wp-
content/uploads/2012/06/Dosage_Patenting_in_Personalized_Medicine.pdf.
Note, however, that Japans laws are showing slight movement toward the
United States approach. Id. at 9. For patent law regarding dosage regimens in
other countries, see European Patent Convention, Convention on the Grant of
European Patents art. 54, Oct. 5, 1973, https://www.epo.org/law-practice/legal-
texts/html/epc/2013/e/ar54.html; R. Stephen Crespi, Inventiveness in
Biological Chemistry: An International Perspective, 73 J. PAT. & TRADEMARK
OFF. SOCY 351, 36568 (1991) (discussing the European Patent Office
guidelines for patentability); Martin Maclean, Dosage Regimen Patent Claims
in Europe, INTELL. PROP. TODAY, Sept. 2009, at 17; Oksana Mitnovetski &
Dianne Nicol, Are Patents for Methods of Medical Treatment Contrary to the
Ordre Public and Morality or Generally Inconvenient?, 30 J. MED. ETHICS
470, 47174 (2004); see also Bristol-Myers Squibb Co. v. Baker Norton
Pharmaceuticals Inc. and Napro Biotherapeutics Inc., [2001] EWCA (Civ) 414,
http://www.bailii.org/ew/cases/EWCA/Civ/2001/414.html; Actavis UK Ltd. v.
Merck & Co. Inc., [2008] EWCA (Civ) 444, http://www.eplawpatentblog.com
/2010/February/%5B2008%5D%20EWCA%20Civ%20444.pdf; Nobuta Yokota,
LIFE SCI. IP FOCUS, JAPAN: PATENT ELIGIBILITY EXPANDED 2527 (7th ed., ,
2009), http://www.kyowapatent.co.jp/en/info/data/091026.pdf; Invitation for
Public Comments on Draft Revision of Examination Guidelines for
Industrially Applicable Inventions and Draft Revision of Examination
Guidelines for Medicinal Inventions, JAPAN PAT. OFF. (Aug 6, 2009),
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the rapid change in patent law has posted great challenges to
dosage regimen patents. The first seminal case was KSR,
which reshaped the non-obviousness jurisprudence of patent
law.122 Before KSR, the Graham factors were used to test the
obviousness of the invention by showing that a skilled artisan
in the art would have been motivated to combine the teachings
of the prior art references to achieve the claimed invention with
a reasonable expectation of success, which was called the
teaching-suggestion-motivation test.123 The U.S. Supreme
Court rejected the rigid Graham test in KSR and instead
looked for a broad range of indicators: an apparent reason to
combine known elements, including market pressure with
finite number of solutions, useful technology for improving
similar devices, obvious to try, the old teaching-suggestion-
motivation test, and so on.124 This new standard has been a
much harder test to fulfill for dosage regimen applications,
because they can be easily characterized as arising out of
known techniques, obvious to try, or based on teaching-
suggestion-motivations from prior art.125
https://www.jpo.go.jp/cgi/linke.cgi?url=/iken_e/comments_iryou.htm; Amy
Feng, Take Local Practice Into Account, MANAGING INTELL. PROP. (June 1,
2008), http://www.managingip.com/Article/1941461/Take-local-practice-into-
account.html; John A. Tessensohn & Shusaku Yamamoto, Japanese Biotech
Patenting Strategies in the Era of Follow-on Biologics, 28 BIOTECHNOLOGY L.
REP. 483, 48485 (2009) (discussing Japanese follow-on biologics guidelines);
Peter K. Yu, From Pirates to Partners: Protecting Intellectual Property in
China in the Twenty-First Century, 50 AM. U. L. REV. 131, 13254 (2000)
(discussing the change in Chinas policies toward intellectual property in
response to US trade sanctions following World War II).
122. KSR Intl Co. v. Teleflex, Inc., 550 U.S. 398, 420 (2007) (holding that
the obviousness inquiry should consider whether the invention was obvious
from the view point of one having ordinary skill in the art).
123. Id. at 40607 (citing Graham v. John Deere Co. of Kansas City, 383
U.S. 1, 1718 (1966)).
124. Id. at 41422.
125. Enzo Furrow, Analyzing the Laws, Regulations, and Policies Affecting
FDA-Regulated Products: Pharmaceutical Patent Life-Cycle Management After
KSR v. Teleflex, 63 FOOD & DRUG L. J. 275, 30106 (2008) (discussing the non-
obviousness requirement as it applies to pharmaceuticals). For a new dosage
regimen patent that was held non-obvious, see generally Braintree Lab., Inc.
v. Novel Lab., Inc., 749 F.3d 1349, 1359 (Fed. Cir. 2014). For new dosage
regimen patents that were held obvious, see Allergan, Inc. v. Sandoz, Inc., 726
F.3d 1286, 1288 (Fed. Cir. 2013); Bayer Healthcare Pharmaceuticals, Inc. v.
Watson Pharmaceuticals, Inc., 713 F.3d 1369, 1377 (Fed. Cir. 2013);
Hoffmann-La Roche, Inc. v. Apotex, Inc., 748 F.3d 1326, 1335 (Fed. Cir. 2013);
Warner Chilcott Co. v. Teva Pharmaceuticals USA, Inc., 37 F.Supp.3d 731,
740 (D. Del. 2014).
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One recent decision that demonstrates the vigorousness of
the KSR test in dosing patents is Warner Chilcott.126 The
patent owner brought suit against the generic drug company
for infringing two patents, which were directed to a delayed-
release formulation of the osteoporosis drug Atelvia.127 The new
formulation combined the active ingredient risedronate with
ethylene diamine tetraacetic acid (EDTA) and was developed to
address a non-absorption problem that occurred with
osteoporosis drugs taken with food.128 The presence of calcium
in common food captures the active ingredient in the drug,
preventing it from entering the bloodstream; EDTA in the new
formulation is able to chelate with calcium and blocks its
reaction with the active ingredient.129 The closest prior art
disclosed two mechanisms for increasing absorption with
EDTA: (1) chelation, as described above; and (2) permeability
enhancement, a process in which large doses of EDTA spread
the pathways between intestinal cells, allowing more . . .
[risedronate to enter] into the bloodstream.130 The patented
invention chose to use the first mechanism instead of the
second one.131
The court reasoned that the prior art contained all the
necessary elements and known ways to arrange them and
determined that a skilled artisan would be motivated to avoid
using large amount of EDTA (second mechanism); therefore,
despite the finding of a long-felt, unmet need in the market and
defendants own skepticism of this method, the invention was
ruled to have produced expected results and was obvious.132
This ruling underlines the high non-obviousness standard KSR
created for dosage regimen patents and highlights the
uncertainty the smacks of hindsight can impose on a
multimillion-dollar product.
The second set of landmark decisions, Mayo and Myriad
Genetics, addressed patent-eligible subject matter for dosage
126. Warner Chilcott Co. v. Teva Pharmaceuticals USA, Inc., 89 F. Supp.
3d 641 (D. N.J. 2015).
127. Id. at 64647.
128. Id at 646.
129. Id at 645.
130. Id at 646.
131. Id.
132. Id. at 68082.
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regimen and diagnostic tools under 35 U.S.C. § 101.133 In Mayo,
the patent was directed to a method of optimizing a patients
dosage regimen of thiopurine drugs by administering the drug
to a patient and determining the level of drug metabolites in
the patients body, which would indicate whether the dosage
should be increased or decreased.134 The Court unanimously
held that these metabolic diagnostic claims for detecting a
correlation between a metabolite and the likelihood of
responding to a drug are unpatentable laws of nature and
affirmed that the machine-and-transformation test is not the
exclusive test for patentability.135 Mayo also devised a two-part
test for those claims that claim patent-eligible applications of
laws of nature: first, determine whether the claims at issue are
directed to a patent-ineligible concept.136 If the answer is yes,
then we next consider the elements of each claim both
individually and as an ordered combination to determine
whether additional elements transform the nature of the
claim into a patent-eligible application.137 Since using the
correlation between dosage and metabolite levels in the blood
to optimize ones dosage regimen was purely conventional and
obvious, it was insufficient to transform the invention into a
patentable subject matter.138
Soon after Mayo, Myriad addressed claims directed to
isolated DNA sequences including BRCA1 and BRCA2 genes
and corresponding human-made cDNAs in which the variations
of these sequences indicated the likelihood of an individual to
develop breast or ovarian cancer.139 The Supreme Court held
that isolated genomic DNA sequences are natural products and
ineligible for patent protection, while cDNA is patent-eligible
subject matter.140 In a subsequent case, the Federal Circuit
133. Mayo Collaborative Servs. v. Prometheus Lab., Inc., 132 S. Ct. 1289
(2012); Assn for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107
(2013); see also 35 U.S.C. § 101 (2012).
134. Mayo, 132 S. Ct. at 129495.
135. Id. at 1303 (stating the machine-or-transformation test does not
trump the law of nature exclusion).
136. Id. at 129798.
137. Id.
138. Id. at 1297; see also Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788
F.3d 1371 (2015).
139. Assn for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct.
2107, 211213 (2013).
140. Id. at 211819.
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also held the method claims of comparing a patients BRCA
with wild-type BRCA genes to identify mutations as
unpatentable subject matter under theMayo framework.141
The Mayo and Myriad cases reshaped the subject-matter
eligibility landscape under 35 U.S.C. § 101 (2012) and
narrowed the scope of the initial screening for patent eligibility.
They raised many uncertainties about how this expanded law-
of-nature concept will affect patent protection of diagnostic
methods relying on the correlations between a biomarker or
genetic traits and certain physiological conditions, such as
responses to drugs. The progenies PerkinElmer and Ariosa
highlight the outcry from biotech and pharmaceutical
companies.142
First, soon after the Mayo decision, the Federal Circuit
invalidated a diagnostic claim under the two-part test.143 This
claim in PerkinElmer involved a method for determining the
risk of fetal Downs syndrome by measuring screening markers
and comparing the marker levels with an empirical frequency
distribution of the markers in affected and unaffected
pregnancies.144 Without an additional step after determining
the correlation, the Federal Circuit characterized the claim as a
mental step, and the correlation between marker levels and the
risk of Downs syndrome as a law of nature.145 The measuring
steps were routine and conventional, thus insufficient to make
the claims patent-eligible.146
More recently, in Ariosa, the Federal Circuit again
invalidated similar claims directed to a novel method of
detecting cell-free fetal DNA in maternal plasma or serum to
determine fetal characteristics.147 This invention provided an
alternative for prenatal diagnosis of fetal DNA that avoids the
risks of widely-used techniques that took samples from the
fetus or placenta.148 Despite this significant contribution to
141. In re BRAC1- and BRAC2-Based Hereditary Cancer Test Patent Litig.
v. Ambry Genetics Corp., 774 F.3d 755, 76465 (Fed. Cir. 2014).
142. PerkinElmer, Inc. v. Intema Ltd., 496 Fed. Appx. 65 (Fed. Cir. 2012);
Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).
143. PerkinElmer, 496 Fed. Appx. at 66.
144. Id. at 6668.
145. Id. at 7071.
146. Id. at 71.
147. Ariosa, 788 F.3d at 1373.
148. Id.
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public health, the court ruled that this discovery is a law of
nature and application of routine and conventional technique
did not tip the balance of patentability.149 Personalized
medicine, as discussed in Section I, requires establishing the
correlation of genetic variations with a disease and/or patients
physiological responses to dosage regimens.150 This demands
significant investment in testing, data collection, and analysis;
however, Mayo and Myriad cast grave doubts upon the
patentability of the resulting discoveries.
Collectively, KSR, Mayo, and Myriad raised a nearly
unobtainable standard for dosage regimen patent protection,
even for the pre-personalized medicine era. Mayos two-part
test effectively eliminated most method claims of dosing
patents that rely on correlations between drug dosing and
patients responses as a way to optimize dosage regimens,151
and it delivered the same blow to diagnostic patents based on
genomic screening in Myriad, unless a novel detection method
is used.152 Furthermore, the Court in Myriad declared the
genes responsible for certain diseases are not patentable.153
Even if a dosage regimen is determined for a patient subgroup
and deemed patentable subject matter, seeking patent
protection on it will then face the high non-obviousness
standard in KSR.154
In the era of personalized medicine, most of the genetic
testing and dosage design will be performed outside of the
pharmaceutical companies.155 Even when the companies decide
to conduct their own research to determine dosage regimens for
subgroups of patients, the methods of dosing will not be
149. Id. at 137778.
150. See sources cited supra note 41 and accompanying text.
151. Mayo Collaborative Servs. v. Prometheus Lab., Inc., 132 S. Ct. 1289,
12991300 (2012) (suggesting that the patent merely states the steps
necessary to apply a law of nature and tells doctors to apply it).
152. Assn for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct.
2107, 211213 (2013) (discussing the techniques used in Myriads patents).
153. Id. at 211920.
154. KSR Intl Co. v. Teleflex, Inc., 550 U.S. 398, 420, 428 (2007); see 35
U.S.C. §§ 101, 103 (2012) (requiring that, in order to receive a patent, the
invention must satisfy non-obviousness grounds of § 103 and patentable-
subject matter grounds of § 101, separately).
155. See supra note 119 and accompanying text.
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patentable under Mayo.156 Dosage regimens themselves are in
theory patentable, but overcoming KSR will require some
rather unexpected results. Given how most researchers will be
using similar next-generation sequencing technologies to test a
patient for an optimized dosage regimen, it would be hard not
to fall into the obvious to try or using a technology to solve a
similar problem category.157 In light of these developments in
patent law, technological development, and advancing medical
practice, dosage regimen patents will decline in number and
significance. Therefore, pharmaceutical companies need to seek
alternative strategies to maintain their competitive edge in the
market.
C. POSSIBLE STRATEGIC RESPONSES TO THE CHALLENGE OF
DOSAGE REGIMEN PATENTS IN THE ERA OF PERSONALIZED
MEDICINE
1. Recommendation 1: Continue seeking patent protection.
The pharmaceutical industry is one of three technology-
based industries in which the patent virtually equals the
product. Since capital investment in the pharmaceutical
industry disproportionally is directed to . . . research and
clinical trials . . . patent exclusivity is the only effective way to
protect and receive a return on that investment.158 Therefore,
the first recommendation focuses on strategies to help navigate
the current jurisprudence of dosage regimen patents.
Novel Detection/Measurement Methods: The Supreme
Court stated in Mayo [p]urely conventional or obvious [pre]-
solution activity is normally not sufficient to transform an
unpatentable law of nature into a patent-eligible application of
such a law.159 Thus, a method for diagnosing disease A by
detecting the presence or absence of a biomarker B will most
likely be rendered unpatentable subject matter unless the
invention uses unconventional or novel detection platforms. For
example, say biomarker B is being measured with a new
156. Mayo, 132 S. Ct. at 12991300; see also sources cited supra note 125
and accompanying text.
157. See KSR, 550 U.S. at 417, 421.
158. Bruce Lehman, The Pharmaceutical Industry and the Patent System,
WAKE FOREST U. 7 (2003), http://users.wfu.edu/mcfallta/DIR0
/pharma_patents.pdf.
159. Mayo, 132 S. Ct. at 1298.
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antibody or a novel fluorescent tag. This scarifies the scope of
the original claim in exchange for passing the Mayo test. When
choosing this strategy, the strength and novelty of the new
detection method plays a large role in generating value for the
claim.
Additional Steps: The second step of theMayo test requires
additional elements to transform the nature of the claim into
a patent-eligible application.160 In Classen, the claim appended
a physical administration step after the diagnostic step and
successfully converted an abstract diagnostic test to a
patentable application.161 The patent was directed toward [a]
method of immunizing a mammalian subject, which is
comprised of a screening step followed by an immunization step
in which the subject was physically immunized based on the
results.162 The Federal Circuit held that the addition of this
physical step moves the . . . claims through the coarse filter of
§ 101 . . . from principle to application.163 This method may
have enforceability limitations that will be discussed in
Recommendation 2. Alternatively, a step can be added to create
a non-natural, man-made product or intermediate that is
detected instead of the biomarker itself. For example, a
chemical tag can be used to react with the biomarker and then
resulting complex will be measured through conventional
methods as an indicator for the disease. Since a man-made
complex is generated, it can arguably satisfy § 101.
Other possibilities: Adjudicated cases so far have only
addressed the patentability of one biomarker/one disease
correlation. It is unclear whether the detection of multiple
biomarkers (A, B, and C) to diagnose one or more concurrent
diseases would pass § 101. A strict reading of the Mayo test
would still render it a law of nature, but a creative use of a
biomarker combination might qualify it as an unconventional
or non-routine detection approach.
In the meantime, after the denial of an en banc hearing
from the Federal Circuit, a petition for certiorari was filed with
the U.S. Supreme Court to revisit the Mayo test as applied in
160. Id. at 1297.
161. Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057, 1065
(2011).
162. Id. at 106061.
163. Id. at 1068.
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the Ariosa case.164 Echoing Judge Linns concurrence in Ariosa,
academic and professional commentators urged the Court to
distinguish the new discovery in Ariosa with the well-known
correlation in Mayo and reexamine the sweeping language in
the precedent.165 If the Court decided to grant certiorari, it
could possibly [be] the biggest challenge to patent eligibility
since . . . [the] Bilski v. Kappos decision in 2010,166 and the
recommendations elaborated in this note would need to be
adjusted accordingly.
2. Recommendation 2: Pursue patent rights cautiously and
seek collaboration with hospitals or independent laboratories.
As discussed above, the Supreme Court precedents limit
dosage regimen patents to narrow instrument-, method-, or
drug-specific claims.167 Assuming valuable dosage regimen
patents are obtainable in the current judicial environment, this
recommendation focuses on the enforceability of these rights in
the era of personalized medicine and advocates for
pharmaceutical companies to seek more proactive
collaborations with medical facilities.
Regardless of the eventual outcome in Ariosa, two
components are necessary in personalized medicine: a genetic
testing step to determine dosage regimen and a drug
administration step. The nature of this approach may raise
concerns as to who will be the inventor/owner of the first step,
and whether these patents are enforceable if the two steps are
performed by separate entities. Turning genetic information
into actionable medical decisions requires testing of a large
number of patients, data collection, and analysis to establish
the correlation between the patients genetic variations and
effective dosage regimens.168 We have also come to the
conclusion that this correlation alone would not be enough to
164. Hal Wegner, Top Ten No. (1) Patent Case: Sequenom v. Ariosa at the
Supreme Court, L.A. INTELL. PROP. L. ASSN (Dec. 7, 2015),
http://www.laipla.net/top-ten-no-1-patent-case-sequenom-v-ariosa-at-the-
supreme-court/.
165. Paul Cole, Guest Post: Ariosa v SequenomA Path to the Supreme
Court?, PAT. DOCS BLOG (Dec. 14, 2015), http://www.patentdocs.org/2015/12
/guest-post-ariosa-v-sequenom-a-path-to-the-supreme-court.html.
166. Wegner, supra note 164.
167. See supra Part II.B.
168. Myers, supra note 56, at 1415.
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pass the § 101 test.169 Consequently, to retain patent rights in
dosage regimens, the pharmaceutical companies would have to
invest significantly to invent both components and draft two-
step claims to cover both dosage regimen determination and
drug administration parts. Alternatively, they could choose to
pursue only composition patents on new chemical entities and
leave the diagnostic and administration steps to medical
professionals or others. However, before choosing one option
over the other, we need to take a close look at the enforceability
of two-step claims in the context of personalized medical
practice.
Doctor/Independent Laboratory: Following an initial
diagnosis, an oncologist takes a blood sample from his or her
patient and sends it to an independent laboratory for whole
genome sequencing. The laboratory then tests the genetic
variations and transmits the results back to the hospital,
where the doctor makes the dosage regimen decisions
accordingly and administers medications to the patient. To
infringe the patentees two-step patent directly or indirectly, all
steps in the claim have to be completed by one entity,170 and in
our scenario, one party has to be conducting the genetic test,
determining the dosage regimen, and administrating the drugs.
However, the doctor and independent laboratory together
perform these steps,171 while neither has done all by itself;
thus, there will be no infringement directly or indirectly. It is
unlikely the court will find an agency relationship between the
hospital and the laboratory, since they do not have controls
over the others actions.172 Therefore, a two-step patent will be
hard to enforce in this scenario.
Doctor/Laboratory in One Hospital: The oncologist takes a
sample from the patient and sends it for genetic testing in a
laboratory down the hall in the same hospital. The doctor gets
169. See supra Part II.B.
170. See Limelight Networks, Inc. v. Akamai Techs., Inc., 134 S. Ct. 2111,
2115 (2014) (holding that a defendant may [not] be liable for inducing
infringement of a patent . . . when no one has directly infringed the
patent . . . .).
171. The patient may be performing part of the steps as well, depending on
how the claims are drafted.
172. Akamai Techs., Inc. v. Limelight Networks, Inc., 629 F.3d 1311, 1321
(2010) ([T]here is no indication that an agency relationship arises when one
party simply provides direction, no matter how explicit, to another party. All
the elements of an agency relationship must be present.).
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the results and determines the optimal dosage regimen for the
patient, who later is administered the medication. Patentee, in
this case, is able to sue the hospital, the doctor and the
laboratory, arguing that the doctor and laboratory are acting as
agents for the hospital or under contractual obligations to
perform steps of the claim.173 Although the doctor or laboratory
can characterize themselves as independent contractors, the
Federal Circuit expressly stated [a] party that engages
another to perform a step of a claimed method as its agent
cannot escape liability [for patent infringement] simply by
designating its agent an independent contractor if all the
elements that otherwise reflect an agency relationship are
present.174
In light of the enforceability landscape of two-step patents,
should pharmaceutical companies obtain a sole composition
patent on their new drugs or risk investing billions of dollars to
further pursue personalized dosage regimens inventions and
patents? There are several factors to take into consideration
when making this determination. First, the medical complexity
of the disease will affect the cost-benefit analysis of the
personalized dosage development. The high cost of drug
development is disproportionally devoted to research and
clinical trials.175 Therefore, the extra expenses in additional
research efforts of developing personalized dosage regimens
must be evaluated in light of the market exclusivity they can
generate. For example, in cases where the drugs under
development are effective for treating most of the genetic
subgroups or the dosage regimens are not drastically different
across subgroups, the cost can be reduced to a level that
justifies the extra capital.
Secondly, the access to diverse patients is becoming more
and more important in developing these genetic traits/drug
response correlations. In the one size fits all era, the clinical
trial sets criteria for patient sample selections such as age,
gender, disease stage, and medical history.176 Unlike these
173. Id. at 1320 ([T]here can only be joint infringement when there is an
agency relationship between the parties who perform the method steps or
when one party is contractually obligated to the other to perform the steps.).
174. Id.
175. Lehman, supra note 158.
176. Learn About Clinical Studies, CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/about-studies/learn (last updated Dec. 2015).
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parameters, genetic variations cannot be selected prior to
actual testing, significantly increasing the uncertainty and
costs of such efforts. Therefore, having access to diverse
patients is paramount to having sufficient clinical data for
determining dosage regimen correlation.
Moreover, the structure of the genetic testing industry will
influence the enforceability of these dosage regimen patents.
Currently, in terms of clinical testing revenue, hospital
laboratories account for approximately sixty percent while
independent laboratories represent thirty-five percent.177 They
are both expected to grow at the same rate and [be] consistent
with [the] overall clinical testing market growth in the next
five years.178 According to our analysis of the two scenarios
above, the patentee can enforce the two-step patents about
sixty percent of the time. Finally, alternative means of
exclusivity, such as FDA regulations and non-patent
intellectual property rights, need to be considered. These will
be discussed in the next section.
To minimize these uncertainties and risks, collaboration
with hospitals or independent laboratories is worth exploring.
Delegating the dosage regimen design to medical facilities or
even testing centers could significantly decrease
pharmaceutical development costs, freeing up funds for more
horizontal research silos to investigate new chemical entities.
Additionally, most pharmaceutical companies are using
advertisements and government registries to seek potential
clinical trial participants.179 Hospitals and independent
laboratories will provide even more access to first-hand data on
patients response to drugs and their feedback on
individualized dosage regimens.
177. CLINICAL LAB. MGMT. ASSN THINKLAB, WASH. G-2 REPORTS
ADVISORY SERVS., LABORATORY INDUSTRY OUTLOOK 20102011 4 (2010),
https://c.ymcdn.com/sites/www.clma.org/resource/resmgr/Professional_Develop
ment_-_Past_ThinkLabs/305_Stephanie_Murg.pdf.
178. The Future for Hospital and Independent Labs in the U.S. Clinical
Testing Market, supra note 21.
179. See, e.g., Clinical Trials, AVANIR PHARMACEUTICALS,
http://www.avanir.com/products/clinical-trials (last visited Feb. 22, 2016);
CLINICAL TRIALS.GOV, https://clinicaltrials.gov/ct2/home (last visited Feb. 28,
2016) (providing a search tool for completed and ongoing clinical trials).
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3. Recommendation 3: Seek non-patent exclusivity.
To incentivize continuing innovation, the FDA has
implemented numerous provisions to extend market
exclusivity; this non-patent exclusivity allows pharmaceutical
companies to market their products without competition from
generics, gaining significant financial benefits.180 The Food,
Drug, and Cosmetic Act provides four exclusivity opportunities:
(1) new chemical entity exclusivity; (2) clinical investigation
exclusivity; (3) orphan drug exclusivity; and (4) pediatric
exclusivity.181 A pharmaceutical manufacturer can claim new
chemical entity exclusivity by introducing a new active
moiety.182 Additionally, it can receive clinical investigation
exclusivity by conducting additional clinical trials for new
dosage formulations183 and new indications, or change from
prescription to over-the-counter. Development of orphan drugs,
those intended to treat diseases and conditions that affect
200,000 or less Americans, can afford the manufactures with
seven years of market exclusivity after FDA approval.184
Pediatric exclusivity, carrying with it an additional six-month
extension, is granted to a sponsor with an approved new drug
180. See FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: APPLICATIONS
COVERED BY SECTION 505(b)(2) 36 (Oct. 1999),
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm079345.pdf; see also
James R. Copland, Administrative Compensation for Pharmaceutical- and
Vaccine-Related Injuries, 8 IND. HEALTH L. REV. 277, 286 (2011); Pamela
Politis, Transition from the Carrot to the Stick: The Evolution of
Pharmaceutical Regulations Concerning Pediatric Drug Testing, 12 WIDENER
L. REV. 271, 272 (2005).
181. GUIDANCE FOR INDUSTRY: APPLICATIONS COVERED BY SECTION
505(b)(2), supra note 180, at 7; Renu Lal, FDA/CDER SBIA Chronicles:
Patents and Exclusivity, CTR. FOR DRUG EVALUATION & RES.: SMALL BUS. &
INDUS. ASSISTANCE 23 (May 19, 2015), http://www.fda.gov/downloads/Drugs
/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM447307.pdf.
182. Lal, supra note 181, at 2.
183. Tracey Walker, FDA Approves Higher Dose, Less-Frequent Dosing
Regimen for Copaxone, MODERNMEDICINE NETWORK (Jan. 30, 2014),
http://formularyjournal.modernmedicine.com/formulary-
journal/content/tags/copaxone/fda-approves-higher-dose-less-frequent-dosing-
regimen-copaxo; see also Dose-Response Information to Support Drug
Registration, 59 Fed. Reg. 55,972, 55,97276 (Nov. 9, 1994) (providing
guidance for including dose-response information in drug registration
applications); Ryan Abbott & Ian Ayres, Evidence and Extrapolation:
Mechanisms for Regulating Off-Label Uses of Drugs and Devices, 64 DUKE L.
J. 377, 37778 (2014).
184. Lal, supra note 181, at 2.
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application who conducts a pediatric study in response to a
written request from FDA.185
Personalized medicine enabled by next-generation DNA
sequencing will also raise significant regulatory challenges for
the FDA and other federal and state agencies.186 Ability to
quickly adapt to the changes and communicate them effectively
will help lower the hurdle to the market and meet consumer
needs before competitors emerge.
185. Id.; see also Politis, supra note 180, at 278 (citing the Food and Drug
Administration Modernization Act of 1997).
186. See Barbara J. Evans, The Limits of FDAs Authority to Regulate
Clinical Research Involving High-Throughput DNA Sequencing, 70 FOOD
DRUG L. J. 259, 275 (2015) (discussing the right to access variant genetic
sequences under the Health Insurance Portability and Accountability Act
Privacy Rule); Gail H. Javitt & Katherine Strong Carner, Regulation of Next
Generation Sequencing, 42 J.L. MED. & ETHICS 9, 9 (Supp. Fall 2014) ([T]he
availability of high-throughput NGS [next generation sequencing] methods
has led to a proliferation of potential and actual clinical applications for
NGS.); Jessica Elizabeth Palmer, Genetic Gatekeepers: Regulating Direct-to-
Consumer Genomic Services in an Era of Participatory Medicine, 67 FOOD &
DRUG L. J. 475, 488 (2012) ([P]articipatory models offer certain benefits:
reduced costs, quicker subject recruitment, and more avenues for individuals
with rare genetic variations to come forward and bring their information to
the attention of the research community. (internal footnote omitted));
Margaret A. Hamburg, Commr of Food & Drugs, Natl Insts. Health,
Optimizing FDAs Regulatory Oversight of Next Generation Sequencing
Diagnostic Tests (Feb. 20, 2015) (transcript available at,
http://www.fda.gov/downloads/MedicalDevices/
NewsEvents/WorkshopsConferences/UCM439974.pdf); Adam Berger & Zivana
Tezak, FDA Taking Genomic Testing to the Next Level, FDA VOICE (Sept. 8,
2015), http://blogs.fda.gov/fdavoice/index.php/2015/09/fda-taking-genomic-
testing-to-the-next-level/ (describing the FDAs regulatory strategy in response
to the push for next generation clinical testing); Taha A. Kass-Hout & David
Litwack, Advancing Precision Medicine by Enabling a Collaborative
Informatics Community, FDA VOICE (Aug. 5, 2015),
http://blogs.fda.gov/fdavoice/index.php/2015/08/advancing-precision-medicine-
by-enabling-a-collaborative-informatics-community/ (addressing the
challenges the FDA faces in connection with next generation sequencing and
the steps it is taking to assist the industry); Developing Analytical Standards
for NGS Testing, FOOD & DRUG ADMIN. (Nov. 12, 2015),
http://www.fda.gov/downloads/MedicalDevices/NewsEvents
/WorkshopsConferences/UCM468521.pdf; Use of Databases for Establishing
the Clinical Relevance of Human Genetic Variants, FOOD & DRUG ADMIN.
(Nov. 13, 2015), http://www.fda.gov/downloads/MedicalDevices
/NewsEvents/WorkshopsConferences/UCM467421.pdf. But see Mark A.
Rothstein, Currents in Contemporary Bioethics: The Case Against Precipitous,
Population-Wide, Whole-Genome Sequencing, 40 J.L. MED. & ETHICS 682, 682,
68788 (2012) (suggesting that, currently, population-wide, whole-genome
sequencing has negative outcomes).
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4. Recommendation 4: Seek non-patent intellectual property
rights.
Aligned with the companys business objectives, seeking
non-patent intellectual property rights can provide competitive
advantages.187 Trademark law protects marks that identify the
source of a product or service, preventing consumer confusion
and unfair competition.188 In the United States,
pharmaceutical trademarks are subject to the oversight of two
government agencies: the US Patent and Trademark Office
(USPTO) and the FDA.189 During a registration process, the
USPTO considers whether the mark is sufficiently distinctive
and [whether] there is a likelihood of confusion.190 Federal
registration of the brand is not mandatory to use or seek
protection under the Lanham Act but FDA approval is
mandatory.191 The FDA review is independent of USPTO
registration and has a different focus, including promotional
and safety reviews.192 The FDA evaluates whether the
proposed name is overly fanciful so as to be misleading as well
as database searches for common errors and
orthographic/phonological similarities.193 In addition to brand
names, the shape and color of a pill can be protected as trade
dress if they are non-functional and have acquired secondary
187. Robert Cook-Deegan et al., The Next Controversy in Genetic Testing:
Clinical Data as Trade Secrets?, 21 EUR. J. HUM. GENETICS 585, 587 (2013)
(Policies to reward or require data sharing can prevent some foreseeable
problems caused by limited access to proprietary data about the clinical
significance of genetic variations.); Roseann B. Termini & Amy Miele,
Copyright and Trademark Issues in the Pharmaceutical IndustryGeneric
Compliance or Brand Drug ImitatingCopycat or Compliance, 84 PA. BAR
ASSN Q. 34, 3637, 3944 (2013).
188. Termini & Miele, supra note 187, at 35, 38.
189. Nick de la Torre & Jennifer Theis, Pharmaceutical Trademarks 2012:
United States, in Pharmaceutical Trademarks 2012  A Global Guide 61




192. Id.; see also Steve Anderson et al., Navigating the Challenges of U.S.
Pharmaceutical Trademark Clearance Research, PHARMACEUTICAL
PROCESSING (Apr. 14, 2010, 10:13 AM),
http://www.pharmpro.com/article/2010/04/navigating-challenges-us-
pharmaceutical-trademark-clearance-research.
193. Torre & Theis, supra note 189; see also Anderson et al., supra note
192.
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meaning (acquired distinctiveness).194 Pharmaceutical
trademarks are challenging and labor intensive to obtain,195
and the high drug cost still tops the list of health care
concerns.196 Therefore, caution must be used when investing
extensively in building pharmaceutical trademarks.
While trademark law protects the goodwill of a business,
trade secrets are often used as a method to protect
inventions.197 Interpreting the clinical significance of genetic
information depends on access to patients sequencing results
and their clinical information.198 It incentivizes proprietary
genetic test providers to develop privately controlled databases
containing information essential to translate genetic variations
into personalized treatment plans.199 Instead of having patents
with limited lifetimes, it has become common practice to keep
these important databases as trade secrets which could last
permanently.200
One example is Myriad Genetics secret BRCA databases;
when a woman receives genetic testing legally from another
laboratory, medical professionals will not be able to interpret
certain information due to the lack of database access.201 This
strategy has allowed Myriad to remain the dominant BRCA
testing service, even after some of their key patents were
invalidated.202 Thus, pharmaceutical companies that decide to
venture into the personalized medicine realm can learn from
the success of Myriad and use trade secrets to protect the
correlations between genetic variations and drug responses,
which might not pass the patentable subject-matter test after
Mayo. It is worth noting there has been public outcry against
this practice, which argues proprietary databases may hinder
interpretation of genomic data and impede the advance of
194. Termini & Miele, supra note 187, at 41.
195. Anderson, supra note 192.
196. Matthew Perrone, Drug Prices Top Americans List of Health Care
Concerns, ASSOCIATED PRESS (Oct. 28, 2015, 3:44 AM),
http://bigstory.ap.org/article/61fcced3f00747b4be8d0f12c039a8db/drug-prices-
top-americans-list-health-care-concerns.
197. Termini & Miele, supra note 187, at 35.
198. Cook-Deegan, supra note 187, at 585.
199. Id.
200. Id. at 586.
201. Id.
202. Id. at 58687.
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personalized medicine and public health.203 Therefore, policy
and legislative changes need close monitoring.
III. CONCLUSION
Pharmaceutical companies have been relying on dosage
regimen patents to help them maintain and extend market
exclusivity and obtain sufficient profit to recoup investment
and fund further research. A dosage regimen is how a drug is
administered and is at the core of personalized medicine, which
tailors the medical treatment to an individual based on his or
her genetic makeup, age, gender, environmental exposure, and
so on. With the rapid advances of next-generation DNA
sequencing technology, scientists now have unprecedented
access and ability to extract whole human genome data from
patients, which guides them to prescribe the optimal treatment
and/or prevention plan based on their genetic variations.
Consequently, as the personalized medicine era
approaches, genetic testing will be performed in hospitals,
testing facilities, and even patient homes and then translated
to optimal dosage regimen design. This new practice removes
much dosage regimen research outside of the pharmaceutical
companies, thus diminishing dosage regimen patents, which is
already facing tremendous obstacles in light of recent
developments in U.S. patent law. This note proposed four
recommendations for forward-thinking companies to adjust to
these changes and embrace the new era including navigating
current patent system, seeking non-patent exclusivity and
intellectual property rights domestically and internationally,
collaborating with research hospitals, and restructuring
research efforts. These recommendations will help
pharmaceutical innovators adjust their strategies and embrace
new opportunities in the personalized medicine era.
203. Id. at 587.
***
